title: The use of albendazole and diammonium glycyrrhizinate in the treatment of eosinophilic meningitis in mice infected with Angiostrongylus cantonensis.
abstract: Angiostrongylus cantonensis (A. cantonensis) infection causes eosinophilic meningitis in humans. Eosinophilia and a Th2-type immune response are the crucial immune mechanisms for eosinophilic meningitis. CD4+CD25+ regulatory T cells (Treg) are involved in the pathogenesis of A. cantonensis. Diammonium glycyrrhizinate (DG) is a compound related to glycyrrhizin (GL), a triterpene glycoside extracted from liquorice root. We investigated the curative effects and probable mechanisms of therapy involving a combination of albendazole and DG in BALB/c mice infected with A. cantonensis, and compared these with therapy involving albendazole and dexamethasone. We analysed survival time, body weight, signs, eosinophil numbers, immunoglobulin E (IgE), interleukin-5 (IL-5), and eotaxin concentrations, numbers and Foxp3 expression of CD4+CD25+ Treg, worm recovery and histopathology. The present results demonstrated that the combination of albendazole and DG could increase survival time more efficiently and relieve neurological dysfunction; decrease weight loss, eosinophil numbers, concentrations of IgE, IL-5 and eotaxin, the number and expression of Foxp3 of CD4+CD25+ Treg; and improve worm recovery and histopathology changes in treated animals, compared with the combination of albendazole and dexamethasone. The observations presented here suggest that the albendazole and dexamethasone combination could be replaced by the combination of albendazole and DG.
authors.affiliation: Department of Biopharmaceuticals, School of Biotechnology, Southern Medical University, Guangzhou              510515, Guangdong, People's Republic of China.
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.forename: J-P
authors.initials: JP
authors.lastname: Tang
authors.forename: D-R
authors.initials: DR
authors.lastname: Chen
authors.forename: C-Y
authors.initials: CY
authors.lastname: Fu
authors.forename: P
authors.initials: P
authors.lastname: Wang
authors.forename: Z
authors.initials: Z
authors.lastname: Li
authors.forename: W
authors.initials: W
authors.lastname: Wei
authors.forename: H
authors.initials: H
authors.lastname: Li
authors.forename: W-Q
authors.initials: WQ
authors.lastname: Dong
mesh_terms: D015766:Albendazole / Q000008:administration & dosage*; D017185:Angiostrongylus cantonensis / Q000187:drug effects* / Q000472:pathogenicity; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage*; D001835:Body Weight; D003907:Dexamethasone / Q000008:administration & dosage; D004195:Disease Models, Animal; D004802:Eosinophilia / Q000188:drug therapy* / Q000469:parasitology; D005260:Female; D019695:Glycyrrhizic Acid / Q000008:administration & dosage*; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007958:Leukocyte Count; D008581:Meningitis / Q000188:drug therapy* / Q000469:parasitology; D051379:Mice; D008807:Mice, Inbred BALB C; D017206:Strongylida Infections / Q000188:drug therapy* / Q000469:parasitology; D016019:Survival Analysis; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000871:Anthelmintics; D007073:Immunoglobulin E; D019695:Glycyrrhizic Acid; D003907:Dexamethasone; D015766:Albendazole